文献速递肾小球疾病

IgA肾病中λ轻链优势沉积的临床病理意义

Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy.
PubMed 文献 · Kidney Int Rep · 2022-08-17

基于CureGN的IgA肾病队列,440例患者按λ轻链染色强度分为λ优势组(λ减κ强度差≥1+)与κλ共优势组(差<1+),比较两组从肾活检及入组至缓解、eGFR下降50%或进展至终末期肾病的临床过程及病理特征。结果显示两组基线临床特征及临床结局无显著差异,λ优势组内皮细胞增生频率更高(51.1% vs 36.3%,P=0.04),但无其他病理特征显著差异。

要点

  • λ优势组与κλ共优势组在缓解率、eGFR下降50%及进展至ESKD方面无显著差异。
  • λ优势组内皮细胞增生频率显著高于κλ共优势组(51.1% vs 36.3%,P=0.04)。
  • λ优势组IgG染色≥1+的频率略高于κλ共优势组。

核心结论

  • 在IgA肾病中,λ轻链优势与内皮细胞增生增加相关,但与临床结局无关联。

研究设计与样本

  • 基于CureGN的IgA肾病队列,440例患者按λ减κ轻链染色强度差≥1+定义为λ优势组,<1+定义为κλ共优势组。
  • 比较两组从肾活检及入组至缓解(蛋白尿<0.3 g/g)、eGFR下降50%或进展至ESKD的临床过程及病理特征。
  • 234例患者的活检结果由CureGN病理学家复核。

主要发现

  • 440例患者中,两组基线临床特征及缓解率、eGFR下降50%、进展至ESKD率均无显著差异。
  • λ优势组IgG染色≥1+的频率略高于κλ共优势组。
  • 234例复核活检中,λ优势组内皮细胞增生频率为51.1%,κλ共优势组为36.3%(P=0.04)。
  • 两组其他病理特征无显著差异。

关键数值与推荐

  • λ优势组定义:λ减κ染色强度差≥1+;κλ共优势组定义:差<1+。
  • 内皮细胞增生频率:λ优势组51.1% vs κλ共优势组36.3%(P=0.04)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: IgA nephropathy (IgAN) differs from other glomerular diseases by the frequently predominant lambda over kappa light chain deposition. Using the Cure Glomerulonephropathy (CureGN) IgAN cohort, we aimed to determine whether predominant lambda chain deposition is associated with worse clinical outcomes or histopathologic markers of more active disease. METHODS: Patients were categorized based on the intensity of light chain staining. The lambda dominant (LD) group was defined by a difference in intensity score of lambda minus kappa ≥ 1+ and the kappa-lambda codominant (KL) group by a difference < 1+. We compared the clinical course of patients in each category from the time of kidney biopsy and time of enrollment into CureGN to the time of remission (proteinuria < 0.3 g/g), 50% reduction in estimated glomerular filtration rate (eGFR), or progression to end-stage kidney disease (ESKD). We also analyzed differences in histopathologic characteristics between the 2 groups. RESULTS: Among 440 patients, we found no significant differences between groups in baseline clinical characteristics nor in rates of remission, 50% reduction in eGFR, or progression to ESKD. Patients in the LD group had a modestly greater frequency of IgG staining ≥ 1+. The biopsy results of 234 patients reviewed by CureGN pathologists revealed a greater frequency of endocapillary hypercellularity (51.1% vs. 36.3%, P = 0.04) in the LD group, but no other significant difference in histopathologic features. CONCLUSION: In IgAN, we found an association between lambda predominance and increased endocapillary hypercellularity, but no association with clinical outcomes.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ravipati P, Freese RL, Royal V, et al. Clinicopathologic Significance of Predominant Lambda Light Chain Deposition in IgA Nephropathy. Kidney Int Rep. 2022. PMID: 36531879. doi:10.1016/j.ekir.2022.08.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。